IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Positron Emission Tomography in Extrapulmonary Tuberculosis (TUBOGTEP)
This study has been completed.
Sponsor:
Assistance Publique - Hôpitaux de Paris
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01613196
First received: May 14, 2012
Last updated: June 13, 2017
Last verified: June 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Tuberculosis (TB) remains a major public health problem. In extra-pulmonary forms, evidence of bacteriological cure is difficult to be obtained raising the need for other therapeutic assessment tools. 18F-Fluoro-deoxy-glucose (FDG) is a glucose analogue widely used in Positron Emission Tomography (PET). Its uptake is high in cancer cells and in inflammatory cells, especially in active TB foci. The hypothesis is a decrease in the uptake of FDG in the foci of TB during treatment permitting a non-invasive monitoring of therapeutic response. The main objective is to describe the evolution under treatment of the FDG uptake in PET imaging in TB foci in patients cured from lymph node and bone TB. Secondary objectives are to compare the decrease of FDG uptake according to type of location, to define the frequency of localizations revealed by FDG-PET and their impact on therapeutic management at the beginning and the end of treatment, and to describe the evolution of PET in patients not cured.
| Condition | Intervention |
|---|---|
| Extrapulmonary Tuberculosis Lymph Node Tuberculosis Bone Tuberculosis | Other: Positron Emission Tomography with 18F-Fluoro-deoxy-glucose |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Diagnostic |
| Official Title: | Evaluation of Positron Emission Tomography in Extrapulmonary Tuberculosis |
Resource links provided by NLM:
Further study details as provided by Assistance Publique - Hôpitaux de Paris:
Primary Outcome Measures:
- ΣSUVmax variations between the beginning and end of treatment and during follow-up post-treatment, in patients considered cured [ Time Frame: 6 to 18 months ]To measure FDG uptake and evolution, the ΣSUVmax will be used. SUV ("Standard Uptake Value") is defined as tissue concentration of FDG / administered FDG dose / patient weight. ΣSUVmax is the sum of the maximum SUV measured in every TB foci. ΣSUVmax variations between the beginning and the end of treatment, and 6 months later in cases of persistent uptake at the end of treatment will be studied in patients considered cured
Secondary Outcome Measures:
- Change in SUVmax differences in the lesions according to their location in cured patients. [ Time Frame: 6 to 18 months ]SUV variations between the beginning and the end of treatment, and 6 months later in cases of persistent uptake at the end of treatment will be studied in the lesions according to their location in cured patients
- Variations ΣSUVmax and SUVmax in individual lesions in patients not cured. [ Time Frame: 6 to 18 months ]ΣSUVmax variations between the beginning and the end of treatment, and 6 months later in cases of persistent uptake at the end of treatment will be studied in patients not cured.
- Frequency, type and consequences on the therapeutic management of lesions revealed by FDG-PET. [ Time Frame: 6 to 18 months ]Changes in composition or treatment duration will be identified and reported to the information provided by FDG-PET during the study.
| Enrollment: | 55 |
| Actual Study Start Date: | May 2012 |
| Study Completion Date: | December 2016 |
| Primary Completion Date: | September 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Positron Emission Tomography
Positron Emission Tomography
|
Other: Positron Emission Tomography with 18F-Fluoro-deoxy-glucose
2 or 3 FDG-PET scans will be performed in all patients : at inclusion*, end of treatment and 6 months after completion of treatment in cases of persistent uptake *except if already done in the last 15 days. Other Name: PET with 18 FDG
|
Detailed Description:
Longitudinal observational multicenter pilot study. 55 patients to be included Total duration of the study: 51 months. Inclusion period: 27 months Follow up period: 18 to 24 months Number of participating centers: 11 Average number of inclusion per month per center: 1-2
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adults
- Affiliated to a social security system or "AME"
- Patient informed of the objectives and constraints of the study and giving informed consent
- Patient can keep lying valid at least 30 minutes
- Patient not HIV infected or, if infected, with CD4 counts> 200/mm3 for at least 3 months
Exclusion Criteria:
- Suspicion of other concurrent infection
- Severe immunosuppression in case of HIV infection
- Inflammatory disease
- Pregnant or nursing women
- Radiation therapy
- Uncontrolled diabetes
- Prolonged corticosteroid therapy (> 20mg/day)
- Patient unable to sustain injected CT scan and MRI
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01613196
Please refer to this study by its ClinicalTrials.gov identifier: NCT01613196
Locations
| France | |
| BICHAT Claude Bernard | |
| Paris, France, 75018 | |
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
| Principal Investigator: | Patrick Yeni, MD, PHD | Assistance Publique - Hôpitaux de Paris |
More Information
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT01613196 History of Changes |
| Other Study ID Numbers: |
AOM 11080 2011-A01658-33 ( Other Identifier: IDRCB ) |
| Study First Received: | May 14, 2012 |
| Last Updated: | June 13, 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Extrapulmonary tuberculosis FDG-TEP cohorts |
Additional relevant MeSH terms:
|
Tuberculosis Tuberculosis, Osteoarticular Tuberculosis, Lymph Node Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Bone Diseases, Infectious |
Infection Bone Diseases Musculoskeletal Diseases Deoxyglucose Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on August 22, 2017